NASDAQ$LGVN
Longeveron Inc-A · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2022.
Longeveron Inc. reported revenue of $0.3 million and a net loss of $5.2 million for the third quarter ended September 30, 2022. The company's cash and short-term investments were $22.3 million as of September 30, 2022.
- FDA granted Fast Track Designation to Lomecel-B for infants with Hypoplastic Left Heart Syndrome (HLHS).
- Completed enrollment in Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease.
- All approvals in place to initiate enrollment in phase 2 trial for Aging Frailty in Japan.
- Existing cash and short-term investments will be sufficient to cover expenses and capital requirements into the first half of 2024.
Headline financials
Revenue & EPS history
Longeveron · Revenue · Quarterly
$265K
Revenue by segment
Longeveron · $150K total across 1 segment · Q4 2023
- Clinical Trial Revenue$150K—100.0%
Forward guidance
Based on the current operating plan and financial resources, existing cash and short-term investments will be sufficient to cover expenses and capital requirements into the first half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
-5.1%
Avg return
Earnings day
-5.7%
Avg return
5 days after
+23.1%
Avg return
30 days after
35%
7 / 20 earnings
Positive
+10.0%
Q1 2022
Best reaction
-35.7%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.7% | -11.0% | — | |
| Q4 2025 | -4.7% | -0.7% | +6.1% | |
| Q3 2025 | -4.3% | -7.3% | -23.1% | |
| Q1 2025 | -10.1% | -9.4% | -17.4% | |
| Q4 2024 | -9.2% | -5.3% | +2.0% | |
| Q3 2024 | -2.3% | -8.8% | -14.3% | |
| Q2 2024 | -7.5% | -11.3% | -21.8% | |
| Q1 2024 | +3.1% | -1.5% | +106.9% | |
| Q4 2023 | +0.7% | +0.0% | -39.8% | |
| Q3 2023 | -6.7% | -0.5% | +17.6% | |
| Q2 2023 | -6.5% | -12.0% | -25.8% | |
| Q1 2023 | -6.1% | -11.9% | -0.9% | |
| Q4 2022 | -15.5% | -17.5% | -25.0% | |
| Q3 2022 | +5.1% | +2.6% | -14.1% | |
| Q2 2022 | +3.9% | +1.3% | -14.5% | |
| Q1 2022 | +10.0% | +16.2% | -0.7% | |
| Q4 2021 | -14.4% | -7.1% | +37.8% | |
| Q3 2021 | -4.9% | -15.6% | +461.6% | |
| Q2 2021 | -35.7% | -32.9% | -31.1% | |
| Q1 2021 | +1.7% | +17.9% | +35.8% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro